Results 231 to 240 of about 19,912,299 (390)

In silico drug evaluation by molecular docking, ADME studies and synthesis, characterization, biological activities, DFT, SAR analysis of the novel Mannich bases. [PDF]

BMC Chem
Tahiroğlu V, Gören K, Kotan G, Yüksek H.   +3 more
europepmc   +1 more source

Setup of human liver-chips integrating 3D models, microwells and a standardized microfluidic platform as proof-of-concept study to support drug evaluation. [PDF]

Biomater Biosyst, 2022
Cox B, Barton P, Class R, Coxhead H, Delatour C, Gillent E, Henshall J, Isin EM, King L, Valentin JP.   +9 more
europepmc   +1 more source

Evaluation of alcohol, substance and antidepressant drug use of university students during the COVID-19 pandemic

, 2023
Cem BULGAN, Göksun Demirel
openalex   +2 more sources

Effective therapeutic targeting of CTNNB1‐mutant hepatoblastoma with WNTinib

Molecular Oncology, EarlyView.
WNTinib, a Wnt/CTNNB1 inhibitor, was tested in hepatoblastoma (HB) experimental models. It delayed tumor growth and improved survival in CTNNB1‐mutant in vivo models. In organoids, WNTinib outperformed cisplatin and showed enhanced efficacy in combination therapy, supporting its potential as a targeted treatment for CTNNB1‐mutated HB.
Ugne Balaseviciute, Júlia Huguet‐Pradell, Jordi Abril‐Fornaguera, Albert Gris‐Oliver, Alex Rialdi, Elisa Fernández‐Martínez, Carla Montironi, Vanessa Del Pozo, Peter Houghton, Laura Zanatto, Agavni Mesropian, Ieva Keraite, Swan Thung, Carolina Armengol, Pau Sancho‐Bru, Ernesto Guccione, Roser Pinyol, Josep M. Llovet   +17 more
wiley   +1 more source

Manufacturing Uniform Cerebral Organoids for Neurological Disease Modeling and Drug Evaluation. [PDF]

Biomater Res
Hong H, Jun Y, Yoon SB, Park S, Lee J, Jang JW, Nam HJ, Cho H.   +7 more
europepmc   +1 more source

Exploiting metabolic adaptations to overcome dabrafenib treatment resistance in melanoma cells

Molecular Oncology, EarlyView.
We show that dabrafenib‐resistant melanoma cells undergo mitochondrial remodeling, leading to elevated respiration and ROS production balanced by stronger antioxidant defenses. This altered redox state promotes survival despite mitochondrial damage but renders resistant cells highly vulnerable to ROS‐inducing compounds such as PEITC, highlighting redox
Silvia Eller, Susanne Ebner, Carmen Haselrieder, Julia K. Günther, Astrid Drasche, Sophie Strich, Chiara Volani, Andrea Medici, Aleksandar Nikolajevic, Alex Deltedesco, Johannes E. Sigmund, Michael J. Blumer, Martin Hermann, Johanna Vanacker, Gerald Brandacher, Eduard Stefan, Omar Torres‐Quesada, Jakob Troppmair   +17 more
wiley   +1 more source

Bioprinting of a multi-composition array to mimic intra-tumor heterogeneity of glioblastoma for drug evaluation. [PDF]

Microsyst Nanoeng
Lee G, Kim SJ, Choi Y, Park J, Park JK.
europepmc   +1 more source

3D-printed setup for ocular drug delivery evaluation on ex vivo porcine whole eye [PDF]

Felipe M. González‐Fernández, D. Cauzzi, Annalisa Bianchera, Paolo Gasco, Cristina Padula, Patrizia Santi, Sara Nicoli, Silvia Pescina   +7 more
openalex   +1 more source

Three-dimensional in vitro tumor models for cancer research and drug evaluation.

Biotechnology Advances, 2014
Xian Xu, M. Farach-Carson, Xinqiao Jia
semanticscholar   +1 more source

ATF4‐mediated stress response as a therapeutic vulnerability in chordoma

Molecular Oncology, EarlyView.
We screened 5 chordoma cell lines against 100+ inhibitors of epigenetic and metabolic pathways and kinases and identified halofuginone, a tRNA synthetase inhibitor. Mechanistically halofuginone induces an integrated stress response, with eIF2alpha phosphorylation, activation of ATF4 and its target genes CHOP, ASNS, INHBE leading to cell death ...
Lucia Cottone, James Dunford, Eleanor Calcutt, Vicki Gamble, Filiz Senbabaoglu Aksu, Lorena Ligammari, Georgina Wherry, Giorgia Gaeta, John C. Christianson, Adrienne M. Flanagan, Udo Oppermann, Adam P. Cribbs   +11 more
wiley   +1 more source